Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro (Q40423639)

20 September 2017

title

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro (English)

1 reference

20 September 2017

1 reference

H G Jørgensen

1

1 reference

20 September 2017

E K Allan

2

1 reference

20 September 2017

S M Graham

3

1 reference

20 September 2017

J L Godden

4

1 reference

20 September 2017

L Richmond

5

1 reference

20 September 2017

M A Elliott

6

1 reference

20 September 2017

J C Mountford

7

1 reference

20 September 2017

C J Eaves

8

1 reference

20 September 2017

T L Holyoake

9

1 reference

20 September 2017

language of work or name

1 reference

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

19

1 reference

20 September 2017

issue

7

1 reference

20 September 2017

page(s)

1184-1191

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Imatinib mesylate in the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Detection of BCR-ABL kinase mutations in CD34 cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

High-resolution cell division tracking demonstrates the FLt3-ligand-dependence of human marrow CD34 CD38- cell production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Functional consequence of MDR1 expression on imatinib intracellular concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403785

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403785

1 reference

Dimensions Publication ID

20 September 2017

1028517345

0 references

1 reference